- Home
- PLRX vs EYPT Comparison
PLRX vs EYPT Comparison
Compare PLRX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- EYPT
- Stock Information
- Founded
- PLRX 2015
- EYPT 1987
- Country
- PLRX United States
- EYPT United States
- Employees
- PLRX N/A
- EYPT N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PLRX Health Care
- EYPT Industrials
- Exchange
- PLRX Nasdaq
- EYPT Nasdaq
- Market Cap
- PLRX 682.2M
- EYPT 594.5M
- IPO Year
- PLRX 2020
- EYPT 2005
- Fundamental
- Price
- PLRX $10.92
- EYPT $8.72
- Analyst Decision
- PLRX Strong Buy
- EYPT Strong Buy
- Analyst Count
- PLRX 7
- EYPT 8
- Target Price
- PLRX $40.50
- EYPT $25.71
- AVG Volume (30 Days)
- PLRX 509.0K
- EYPT 888.8K
- Earning Date
- PLRX 02-26-2025
- EYPT 03-06-2025
- Dividend Yield
- PLRX N/A
- EYPT N/A
- EPS Growth
- PLRX N/A
- EYPT N/A
- EPS
- PLRX N/A
- EYPT N/A
- Revenue
- PLRX N/A
- EYPT $45,713,000.00
- Revenue This Year
- PLRX N/A
- EYPT N/A
- Revenue Next Year
- PLRX N/A
- EYPT N/A
- P/E Ratio
- PLRX N/A
- EYPT N/A
- Revenue Growth
- PLRX N/A
- EYPT 7.50
- 52 Week Low
- PLRX $10.22
- EYPT $6.90
- 52 Week High
- PLRX $18.92
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- PLRX 35.54
- EYPT 56.13
- Support Level
- PLRX $10.94
- EYPT $7.15
- Resistance Level
- PLRX $12.70
- EYPT $8.25
- Average True Range (ATR)
- PLRX 0.72
- EYPT 0.70
- MACD
- PLRX -0.19
- EYPT 0.07
- Stochastic Oscillator
- PLRX 4.78
- EYPT 68.92
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.